The emerging role of CXCL10 in cancer (Review)

  • Authors:
    • Mingli Liu
    • Shanchun Guo
    • Jonathan K. Stiles
  • View Affiliations

  • Published online on: May 9, 2011     https://doi.org/10.3892/ol.2011.300
  • Pages: 583-589
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The chemokine interferon-γ inducible protein 10 kDa (CXCL10) is a member of the CXC chemokine family which binds to the CXCR3 receptor to exert its biological effects. CXCL10 is involved in chemotaxis, induction of apoptosis, regulation of cell growth and mediation of angiostatic effects. CXCL10 is associated with a variety of human diseases including infectious diseases, chronic inflammation, immune dysfuntion, tumor development, metastasis and dissemination. More importantly, CXCL10 has been identified as a major biological marker mediating disease severity and may be utilized as a prognostic indicator for various diseases. In this review, we focus on current research elucidating the emerging role of CXCL10 in the pathogenesis of cancer. Understanding the role of CXCL10 in disease initiation and progression may provide the basis for developing CXCL10 as a potential biomarker and therapeutic target for related human malignancies.
View References

Related Articles

Journal Cover

July-August 2011
Volume 2 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu M, Guo S and Stiles JK: The emerging role of CXCL10 in cancer (Review). Oncol Lett 2: 583-589, 2011
APA
Liu, M., Guo, S., & Stiles, J.K. (2011). The emerging role of CXCL10 in cancer (Review). Oncology Letters, 2, 583-589. https://doi.org/10.3892/ol.2011.300
MLA
Liu, M., Guo, S., Stiles, J. K."The emerging role of CXCL10 in cancer (Review)". Oncology Letters 2.4 (2011): 583-589.
Chicago
Liu, M., Guo, S., Stiles, J. K."The emerging role of CXCL10 in cancer (Review)". Oncology Letters 2, no. 4 (2011): 583-589. https://doi.org/10.3892/ol.2011.300